Results 141 to 150 of about 84,296 (269)

Use of Computational Models to Investigate Human Targets of Small Ubiquitous Molecules

open access: yesChemBioChem, Volume 27, Issue 8, April 2026.
Chemoinformatics and atomistic modeling were combined to identify protein targets of environmentally and occupationally relevant chemical compounds. A public database linking chemicals, genes, phenotypes, and diseases was used for validation. The study highlights the potential and limitations of these fast, low‐cost computational approaches for early ...
Elena Frasnetti   +5 more
wiley   +1 more source

Engineered ETS1‐Nanoconjugate Restores Immune Homeostasis through Dual Immune‐Vascular Modulation in Relapsing and Progressive Multiple Sclerosis

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 15, 17 April 2026.
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang   +13 more
wiley   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

open access: yesCancer Medicine, Volume 15, Issue 4, April 2026.
This phase II trial investigated the safety and efficacy of opaganib in combination with abiraterone or enzalutamide in patients with castration‐resistant prostate cancer (CRPC). While the study did not meet its disease control efficacy endpoint, there was evidence of clinical activity in a subset of patients.
Jacqueline T. Brown   +12 more
wiley   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen   +7 more
wiley   +1 more source

A Randomized, Double‐Blinded, Placebo‐Controlled QTc Study to Evaluate BIA 28–6156 Effect on Cardiac Repolarization in Healthy Volunteers

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 4, April 2026.
Abstract Mutations in the GBA1 gene, encoding beta‐glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's Disease (PD). BIA 28–6156, an allosteric activator of GCase, is under development for the treatment of GBA‐associated PD.
Isa Peixoto   +5 more
wiley   +1 more source

The Importance of Liver‐Lung Communication in Pulmonary Vascular Diseases

open access: yesComprehensive Physiology, Volume 16, Issue 2, April 2026.
Schematic depicting the key drivers of liver‐lung communication in pulmonary vascular diseases, including hepatic dysfunction, portosystemic shunting, and gut microbial dysbiosis, which together drive pulmonary vascular remodeling. ABSTRACT In normal health, the liver and lungs enjoy a close anatomic, physiologic, and functional relationship.
Navneet Singh   +8 more
wiley   +1 more source

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait

open access: yesHemaSphere, Volume 10, Issue 4, April 2026.
Abstract Sickle cell trait (SCT), the heterozygous state for the hemoglobin S (HbS) mutation, affects roughly 1 in 13 African American individuals and is common among blood donors recruited for antigen‐matched transfusions in sickle cell disease (SCD).
Monika Dzieciatkowska   +17 more
wiley   +1 more source

SPHINGOSINE

open access: yesJournal of Biological Chemistry, 1916
P.A. Levene, C.J. West
openaire   +1 more source

Improved red blood cell storage quality of blood from donors carrying the hypermorphic PIMT I120 variant

open access: yesHemaSphere, Volume 10, Issue 4, April 2026.
Abstract Protein‐l‐isoaspartate O‐methyltransferase (PIMT), encoded by PCMT1, is a repair enzyme that corrects isoaspartyl lesions, preserving protein structure and function. While indispensable for neuronal integrity, its role in red blood cells (RBCs) and transfusion outcomes is incompletely understood.
Shaun Bevers   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy